[{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Citius Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"4","companyTruncated":"Citius Pharmaceuticals \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Minocycline Hydrochloride","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling","graph3":"Citius Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Film, Soluble","sponsorNew":"Citius Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Citius Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Citius Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Public Offering","leadProduct":"Minocycline Hydrochloride","moa":"||Bacterial 70S ribosome","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Citius Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Film, Soluble","sponsorNew":"Citius Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"4","companyTruncated":"Citius Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Suzhou Yabao Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Endocrinology","country":"CHINA","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Endocrinology","graph2":"Phase I","graph3":"Suzhou Yabao Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Suzhou Yabao Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Suzhou Yabao Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"University of North Carolina","sponsor":"CF Therapeutics Development Network Coordinating Center | Seattle Children\u2019s Hospital | Washington University School of Medicine | University of Washington | University of Colorado, Denver | Baylor College of Medicine | University of Alabama at Birmingham","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Genetic Disease","graph2":"Phase II","graph3":"University of North Carolina","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of North Carolina \/ CF Therapeutics Development Network Coordinating Center | Seattle Children\u2019s Hospital | Washington University School of Medicine | University of Washington | University of Colorado, Denver | Baylor College of Medicine | University of Alabama at Birmingham","highestDevelopmentStatusID":"8","companyTruncated":"University of North Carolina \/ CF Therapeutics Development Network Coordinating Center | Seattle Children\u2019s Hospital | Washington University School of Medicine | University of Washington | University of Colorado, Denver | Baylor College of Medicine | University of Alabama at Birmingham"},{"orgOrder":0,"company":"South China Children's Leukemia Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Oncology","graph2":"Phase IV","graph3":"South China Children's Leukemia Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"South China Children's Leukemia Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"South China Children's Leukemia Group \/ Undisclosed"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"F. Hoffmann-La Roche","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Oncology","graph2":"Phase I","graph3":"F. Hoffmann-La Roche","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"F. Hoffmann-La Roche \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"F. Hoffmann-La Roche \/ Undisclosed"},{"orgOrder":0,"company":"University of Colorado, Denver","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Antibiotic","year":"2020","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase IV","graph3":"University of Colorado, Denver","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Colorado, Denver \/ Merck & Co","highestDevelopmentStatusID":"11","companyTruncated":"University of Colorado, Denver \/ Merck & Co"},{"orgOrder":0,"company":"Horizon Health Network","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Horizon Health Network","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Horizon Health Network \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Horizon Health Network \/ Undisclosed"},{"orgOrder":0,"company":"Harvard University Faculty of Medicine","sponsor":"National Institute of Allergy and Infectious Diseases | Sanofi | Harvard School of Public Health (HSPH) | Brigham and Women's Hospital | University of Liverpool | St George's, University of London | University of Florida | Socios en Salud","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Harvard University Faculty of Medicine","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Harvard University Faculty of Medicine \/ National Institute of Allergy and Infectious Diseases | Sanofi | Harvard School of Public Health (HSPH) | Brigham and Women's Hospital | University of Liverpool | St George's, University of London | University of Florida | Socios en Salud","highestDevelopmentStatusID":"8","companyTruncated":"Harvard University Faculty of Medicine \/ National Institute of Allergy and Infectious Diseases | Sanofi | Harvard School of Public Health (HSPH) | Brigham and Women's Hospital | University of Liverpool | St George's, University of London | University of Florida | Socios en Salud"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Oncology","graph2":"Phase I","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Eisai Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Eisai Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eisai Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Eisai Inc \/ Undisclosed"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2018","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bristol Myers Squibb \/ Undisclosed"},{"orgOrder":0,"company":"Ahon Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"CHINA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Ahon Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Ahon Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Ahon Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Vincentage Pharma Co., Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"INDIA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Vincentage Pharma Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vincentage Pharma Co., Ltd \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Vincentage Pharma Co., Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Aosaikang Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibiotic","year":"2022","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Oncology","graph2":"Phase I","graph3":"Aosaikang Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Aosaikang Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Aosaikang Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"Fundacion Agencia Aragonesa para la Investigacion y Desarrollo","sponsor":"Universidad de Zaragoza | Fondation Raoul Follereau | Universit\u00e9 d'Abomey-Calavi | Instituto de Salud Carlos III | Fundaci\u00f3n Anesvad | Tres Cantos Open Lab Foundation | GSK","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Fundacion Agencia Aragonesa para la Investigacion y Desarrollo","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fundacion Agencia Aragonesa para la Investigacion y Desarrollo \/ Universidad de Zaragoza | Fondation Raoul Follereau | Universit\u00e9 d'Abomey-Calavi | Instituto de Salud Carlos III | Fundaci\u00f3n Anesvad | Tres Cantos Open Lab Foundation | GSK","highestDevelopmentStatusID":"8","companyTruncated":"Fundacion Agencia Aragonesa para la Investigacion y Desarrollo \/ Universidad de Zaragoza | Fondation Raoul Follereau | Universit\u00e9 d'Abomey-Calavi | Instituto de Salud Carlos III | Fundaci\u00f3n Anesvad | Tres Cantos Open Lab Foundation | GSK"},{"orgOrder":0,"company":"Karolinska University Hospital","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SWEDEN","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Karolinska University Hospital","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Karolinska University Hospital \/ AstraZeneca","highestDevelopmentStatusID":"1","companyTruncated":"Karolinska University Hospital \/ AstraZeneca"},{"orgOrder":0,"company":"Queen Mary University of London","sponsor":"University of Oxford | KEMRI-Wellcome Trust Research Program | University of Washington | Wageningen University | Zvitambo Institute for Maternal & Child Health | Tropical Gastroenterology & Nutrition Group (TROPGAN) | University of Cambridge | Kenya Medi","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Nutrition and Weight Loss","graph2":"Phase III","graph3":"Queen Mary University of London","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Queen Mary University of London \/ University of Oxford | KEMRI-Wellcome Trust Research Program | University of Washington | Wageningen University | Zvitambo Institute for Maternal & Child Health | Tropical Gastroenterology & Nutrition Group (TROPGAN) | University of Cambridge | Kenya Medi","highestDevelopmentStatusID":"10","companyTruncated":"Queen Mary University of London \/ University of Oxford | KEMRI-Wellcome Trust Research Program | University of Washington | Wageningen University | Zvitambo Institute for Maternal & Child Health | Tropical Gastroenterology & Nutrition Group (TROPGAN) | University of Cambridge | Kenya Medi"},{"orgOrder":0,"company":"Bayer AG","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"GERMANY","productType":"Antibiotic","year":"2016","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase I","graph3":"Bayer AG","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bayer AG \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Bayer AG \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Antibiotic","year":"2014","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Oncology","graph2":"Phase I","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AstraZeneca \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"AstraZeneca \/ Undisclosed"},{"orgOrder":0,"company":"Boehringer Ingelheim GmbH","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"GERMANY","productType":"Antibiotic","year":"2017","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Boehringer Ingelheim GmbH","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Boehringer Ingelheim GmbH \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Boehringer Ingelheim GmbH \/ Undisclosed"},{"orgOrder":0,"company":"Elutia","sponsor":"Berkeley Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Divestment","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Implant","sponsorNew":"Elutia \/ Berkeley Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ Berkeley Biologics"},{"orgOrder":0,"company":"Elutia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Elutia \/ Undisclosed"},{"orgOrder":0,"company":"Elutia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Elutia \/ Undisclosed"},{"orgOrder":0,"company":"Elutia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Elutia \/ Undisclosed"},{"orgOrder":0,"company":"Elutia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Inapplicable","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Elutia \/ Undisclosed"},{"orgOrder":0,"company":"Elutia","sponsor":"Lake Street Capital Markets","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2024","type":"Private Placement","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elutia","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.02,"dosageForm":"Implant","sponsorNew":"Elutia \/ Lake Street Capital Markets","highestDevelopmentStatusID":"15","companyTruncated":"Elutia \/ Lake Street Capital Markets"},{"orgOrder":0,"company":"Elutia","sponsor":"SWK Holdings Corporation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2022","type":"Financing","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ SWK Holdings Corporation","highestDevelopmentStatusID":"15","companyTruncated":"Elutia \/ SWK Holdings Corporation"},{"orgOrder":0,"company":"Elutia","sponsor":"Vizient","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2025","type":"Agreement","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Vizient","highestDevelopmentStatusID":"15","companyTruncated":"Elutia \/ Vizient"},{"orgOrder":0,"company":"Elutia","sponsor":"Berkeley Biologics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Divestment","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0.040000000000000001,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.040000000000000001,"dosageForm":"Implant","sponsorNew":"Elutia \/ Berkeley Biologics","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ Berkeley Biologics"},{"orgOrder":0,"company":"Elutia","sponsor":"HighCape Capital","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Private Placement","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0.029999999999999999,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Implant","sponsorNew":"Elutia \/ HighCape Capital","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ HighCape Capital"},{"orgOrder":0,"company":"Elutia","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Antibiotic","year":"2023","type":"Inapplicable","leadProduct":"Rifampicin","moa":"||Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Elutia","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Implant","sponsorNew":"Elutia \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"Elutia \/ Undisclosed"},{"orgOrder":0,"company":"Pfizer Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Antibiotic","year":"2011","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Undisclosed","graph2":"Phase I","graph3":"Pfizer Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Pfizer Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Pfizer Inc \/ Undisclosed"},{"orgOrder":0,"company":"Hamilton Health Sciences","sponsor":"St George's, University of London | McMaster University","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CANADA","productType":"Antibiotic","year":"2025","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Hamilton Health Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hamilton Health Sciences \/ St George's, University of London | McMaster University","highestDevelopmentStatusID":"10","companyTruncated":"Hamilton Health Sciences \/ St George's, University of London | McMaster University"},{"orgOrder":0,"company":"Michael Hoelscher","sponsor":"Sequella, Inc. | European & Developing Countries Clinical Trials Partnership | German Federal Ministry of Education and Research | Medical Research Council | Radboud University Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2013","type":"Inapplicable","leadProduct":"Rifampicin","moa":"Bacterial DNA-directed RNA polymerase","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Michael Hoelscher","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Michael Hoelscher \/ Sequella, Inc. | European & Developing Countries Clinical Trials Partnership | German Federal Ministry of Education and Research | Medical Research Council | Radboud University Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"Michael Hoelscher \/ Sequella, Inc. | European & Developing Countries Clinical Trials Partnership | German Federal Ministry of Education and Research | Medical Research Council | Radboud University Medical Center"},{"orgOrder":0,"company":"MSIDS Research Foundation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Dapsone","moa":"||Dihydropteroate synthase 1","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"MSIDS Research Foundation","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MSIDS Research Foundation \/ Undisclosed","highestDevelopmentStatusID":"4","companyTruncated":"MSIDS Research Foundation \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for Rifampin
Details :
Rifampicin is a Antibiotic drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Tuberculosis, Pulmonary.
Details :
Rifampicin is a Antibiotic drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Details :
EluPro is designed to prevent post-operative complications, such as infections, in patients with cardiac implantable electronic devices (CIEDs) like pacemakers and defibrillators.
Details :
The agreement aims to provide access to Elutia’s innovative EluPro Antibiotic Eluting BioEnvelope, embedded with rifampin and minocycline, to S3P’s extensive network of 993 acute care facilities.
Details :
EluPro is designed to prevent post-operative complications, such as infections, in patients with cardiac implantable electronic devices (CIEDs) like pacemakers and defibrillators.
Details :
The net proceeds will support the Company’s advancement of its drug-eluting biomatrix product EluPro (rifampin), the world’s first antibiotic-eluting BioEnvelope for Post-surgical Infections.
Details :
EluPro is designed to prevent post-operative complications, such as infections, in patients with cardiac implantable electronic devices (CIEDs) like pacemakers and defibrillators.
Details :
CanGaroo RM featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protection is under evaluation for post-surgical infections.
Details :
Through the divestment, Elutia sells its Orthobiologics business unit to Berkeley Biologics, including Company’s lead drug-eluting product, CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protecti...
Reset All
